RAT PHARMACOKINETICS AND PHARMACODYNAMICS OF A SUSTAINED RELEASE FORMULATION OF THE GABAA α5-SELECTIVE COMPOUND L-655,708
Authors:
- John R. AtackJAJohn R. Atack
- Andy PikeAPAndy Pike
- Ashley ClarkeACAshley Clarke
- Susan M. CookSCSusan M. Cook
- Bindi SohalBSBindi Sohal
- Ruth M. McKernanRMRuth M. McKernan
- Gerard R. DawsonGDGerard R. Dawson
- 1 May 2006
- journal article
- Published by Elsevier in Drug Metabolism and Disposition
- Vol. 34 (5) , 887-893
Abstract
The pharmacokinetic and pharmacodynamic (i.e., receptor occupancy) properties of L-655,708, a compound with selectivity for α5-over α1-, α2-, and α3-containing GABAA receptors, were examined in rats with the aim of developing a formulation that would give sustained (up to 6 h) and selective occupancy of α5-containing GABAA receptors suitable for behavioral studies. Standard rat pharmacokinetic analyses showed that L-655,708 has a relatively short half-life with kinetics in the brain mirroring those in the plasma. In vivo binding experiments showed that plasma concentrations of around 100 ng/ml gave relatively selective in vivo occupancy of rat brain α5-versus α1-, α2-, and α3-containing GABAA receptors. Therefore, this plasma concentration was chosen as a target to achieve relatively selective occupancy of α5-containing receptors using s.c. implantations of L-655,708 (0.4, 1.5, or 2.0 mg) formulated into tablets of various size (20 or 60 mg) containing different amounts of L-655,708 and combinations of low and high viscosity hydroxypropyl methylcellulose (LV- and HV-HPMC). The optimum formulation, 1.5 mg of L-655,708 compressed into a 60-mg tablet with 100% HV-HPMC, resulted in relatively constant plasma concentrations being maintained for at least 6 h with very little difference between Cmax concentrations (125–150 ng/ml) and plateau concentrations (100–125 ng/ml). In vivo binding experiments confirmed the selective occupancy of rat brain α5-over α1-, α2-, and α3-containing GABAA receptors.Keywords
This publication has 28 references indexed in Scilit:
- In vivo labelling of α5 subunit-containing GABA receptors using the selective radioligand [H]L-655,708Neuropharmacology, 2005
- Anxiogenic properties of an inverse agonist selective for α3 subunit‐containing GABAA receptorsBritish Journal of Pharmacology, 2005
- Effects of Hippocampal Injections of a Novel Ligand Selective for the α5β2γ2 Subunits of the GABA/Benzodiazepine Receptor on Pavlovian ConditioningNeurobiology of Learning and Memory, 2002
- GABAAReceptors Containing α5 Subunits in the CA1 and CA3 Hippocampal Fields Regulate Ethanol-Motivated Behaviors: An Extended Ethanol Reward CircuitryThe Journal of Neuroscience, 2001
- Regional Differences in the Inhibition of Mouse In Vivo [3H]Ro 15-1788 Binding Reflect Selectivity for α1 versus α2 and α3 Subunit-Containing GABAA ReceptorsNeuropsychopharmacology, 1999
- Synthesis and Pharmacological Properties of Novel 8-Substituted Imidazobenzodiazepines: High-Affinity, Selective Probes for α5-Containing GABAAReceptorsJournal of Medicinal Chemistry, 1996
- Physiological Parameters in Laboratory Animals and HumansPharmaceutical Research, 1993
- Benzodiazepine concentrations in brain directly reflect receptor occupancy: studies of diazepam, lorazepam, and oxazepamPsychopharmacology, 1990
- Determinants of benzodiazepine brain uptake: lipophilicity versus binding affinityPsychopharmacology, 1987
- A pharmacokinetic/pharmacodynamic/receptor binding model to predict the onset and duration of pharmacological activity of the benzodiazepinesProgress in Neuro-Psychopharmacology and Biological Psychiatry, 1983